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Psychological stress has been implicated as a risk 
factor in the progression of breast cancer, however 
the biological mechanisms are not well understood. 
In animal models of psychological stress, an 
increase in mammary tumour burden and metastatic 
spread has been observed.1 Furthermore, in 
breast cancer cells, the stress hormones cortisol 
and noradrenaline, released as part of the stress 
response, have been shown to promote DNA 
damage through the generation of reactive 
oxygen/nitrogen species.2 
The research presented here aimed to first explore 
the in vitro effects of cortisol by measuring the 
induction of DNA damage and the generation 
of nitric oxide (NO). An in vivo mouse model 
of psychological stress was also employed to 
study the impact of stress on the progression of 
breast cancer, alongside an inhibitor of nitric 
oxide synthase (NOS) (L-NAME). Through 
pharmacological inhibition of the glucocorticoid 
receptor (GR), as well as selective and non-selective 
inhibition of NOS, this research aimed to elucidate 
a mechanism through which stress may impact 
breast cancer progression. 
In mammary tumour cells treated with cortisol, 
an increase in both NO and DNA damage was 
observed. This was abrogated with inhibition 
of the GR, as well as pan-inhibition of NOS and, 
specifically, the isoform inducible NOS (iNOS). 
Cortisol upregulated the expression of iNOS, 
a marker previously suggested as an indicator of 
poor survival in breast cancer.3 Induction of chronic 
stress in a syngeneic mouse model of breast cancer 
had no effect on the growth of the primary tumour; 
however, inhibition of NOS in stressed mice 
significantly decreased tumour volume compared 
to stress alone. A significant increase in tumour 
microvasculature was observed in the primary 
tumours, as there was an increase in metastatic 
sites per mouse in stressed mice, compared to 
the control. This was also reversed through the 
inhibition of NOS. 
This study indicated that stress may impact 
tumourigenic progression through the induction 
of DNA damage, mediated by the release of NO. 
Inhibition of NOS was able to negate the effects of 
stress on tumour growth and metastasis, providing 
an insight into the potential benefits of NOS 
inhibitors in breast cancer treatment. However, 
presentation of this research at the ESMO congress 
raised some potential implications of inhibition of 
NO signalling. Primarily, these included the effects 
of NOS inhibition on haemodynamics, because 
L-NAME has been used previously in a clinical 
setting to increase blood pressure. In future 
studies, this limitation could be resolved through 
cotreatment with antihypertensives, as was the 
case in a previous study that demonstrated the 
growth inhibitory effects of iNOS inhibition in 
breast cancer.4
Discussion also focussed on the effects of 
glucocorticoid signalling in the immune system, 
since previous research has demonstrated that 
stress can adversely affect the immune response 
in breast cancer models, and in patients.5,6 
Furthermore, an increase in the expression of the GR 
has been observed to correlate with poor prognosis 
in oestrogen receptor-negative breast cancer 
patients, indicating that glucocorticoid-mediated 
signalling can influence cancer progression.7 
As such, current trials using novel GR inhibitors 
in breast cancer patients are underway.  Future 
perspectives for this work would seek to use 
pharmacological therapeutics, including using 
selective GR inhibitors in combination with 
NOS inhibitors, in highly stressed patients with 
breast cancer.
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